This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asseray, N.
Right arrow Articles by Bugnon, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asseray, N.
Right arrow Articles by Bugnon, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2002, p. 1591-1593, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1591-1593.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Different Aminoglycoside-Resistant Phenotypes in a Rabbit Staphylococcus aureus Endocarditis Infection Model

N. Asseray,1 J. Caillon,1 N. Roux,1 C. Jacqueline,1 R. Bismuth,2 M. F. Kergueris,3 G. Potel,1* and D. Bugnon1

Laboratoire d'Antibiologie,1 Laboratoire de Toxicologie, UER de Médecine, Nantes,2 Service de Bactériologie, Hospital Pitié Salpétrière, Paris, France3

Received 26 June 2001/ Returned for modification 18 November 2001/ Accepted 25 January 2002

The impact of different types of enzymatic resistance on the in vivo antibacterial activity of aminoglycosides (amikacin, gentamicin, and netilmicin) was studied in the rabbit endocarditis model with four strains of Staphylococcus aureus. Animals were treated in a manner simulating the administration of a single daily human dose. Amikacin had no effect on the three kanamycin-resistant strains despite apparent susceptibility in the disk diffusion test. Gentamicin appears to be the preferable aminoglycoside for treatment of staphylococcal infections.

* Corresponding author. Mailing address: Laboratoire d'Antibiologie Clinique et Expérimentale, Faculté de Médecine, 1 rue Gaston Veil, 44000 Nantes, France. Phone: (33) 2 40 41 28 54. Fax: (33) 2 40 41 28 54. E-mail: gpotel{at}sante.univ-nantes.fr.

Antimicrobial Agents and Chemotherapy, May 2002, p. 1591-1593, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1591-1593.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Goldstein, F. (2007). The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 59: 1-4 [Abstract] [Full Text]  
  • Batard, E., Jacqueline, C., Boutoille, D., Hamel, A., Drugeon, H. B., Asseray, N., Leclercq, R., Caillon, J., Potel, G., Bugnon, D. (2002). Combination of Quinupristin-Dalfopristin and Gentamicin against Methicillin-Resistant Staphylococcus aureus: Experimental Rabbit Endocarditis Study. Antimicrob. Agents Chemother. 46: 2174-2178 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»